Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Dig Liver Dis ; 43(12): 946-52, 2011 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-21907652

RESUMO

BACKGROUND: Autologous haematopoietic stem cells transplantation (HSCT) has been shown to be effective in refractory Crohn's disease. AIM: We analysed the effects of HSCT on the immune response of patients treated for moderate-severe Crohn's disease, refractory or intolerant to multiple drugs. METHODS: Unselected peripheral blood stem cells were collected after mobilisation with cyclophosphamide (CTX) and G-CSF. The conditioning regimen included CTX and rabbit antithymocyte globulin. Blood samples for immunological analyses were collected at baseline, after mobilisation, and 3, 6 and 12 months after transplantation. Immunological analyses evaluated: (1) CD4(+)/CD25(high+)/FoxP3(+) regulatory T cells (T-regs); (2) Toll-like receptor 2-(TLR2) and TRL4-expressing monocytes (CD14(+) cells); (3) IL-12, IL-10, TNF-alpha-production by mitogen-stimulated CD14(+) cells and IFN-gamma production by CD4(+) T cells. Immunological results were compared with healthy donors and associated with clinical and endoscopic response during 12 months of follow-up. RESULTS: Overall, T-regs increased, whilst TLR4-expressing cells, as well as TNF-alpha and IL-10, all higher than healthy donors at baseline, significantly decreased after transplantation. Full responders at T(3) had higher T-regs and lower IFN-gamma and IL12. T-regs decreased and IL12 and TLR2 increased in the only relapsed patient. CONCLUSIONS: HSCT can induce and maintain clinical and endoscopic remission in refractory Crohn's disease, which is associated with immunomodulation.


Assuntos
Doença de Crohn/imunologia , Doença de Crohn/terapia , Transplante de Células-Tronco Hematopoéticas , Imunomodulação , Adulto , Antígenos CD4/análise , Linfócitos T CD4-Positivos/metabolismo , Resistência a Medicamentos , Feminino , Fatores de Transcrição Forkhead/análise , Humanos , Interferon gama/biossíntese , Interleucina-10/biossíntese , Interleucina-12/biossíntese , Subunidade alfa de Receptor de Interleucina-2/análise , Estudos Longitudinais , Contagem de Linfócitos , Masculino , Pessoa de Meia-Idade , Monócitos/imunologia , Monócitos/metabolismo , Linfócitos T Reguladores/imunologia , Receptor 2 Toll-Like/análise , Receptor 4 Toll-Like/análise , Transplante Autólogo , Fator de Necrose Tumoral alfa/biossíntese
2.
FASEB J ; 22(10): 3500-8, 2008 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-18587005

RESUMO

The intracellular expression of the programmed death receptor 1 (PD1) identifies a subset of naive T(reg) cells with enhanced suppressive ability; antigen stimulation results in the surface expression of PD1. Because the role of T(reg) impairments in multiple sclerosis (MS) is still contradictory, we analyzed naive PD1- and PD1+ T(reg) cells in peripheral blood and cerebrospinal fluid (CSF) of relapsing-remitting multiple sclerosis (RR-MS) patients and of healthy control subjects. Results showed that 1) CSF PD1- T(reg) cells were significantly augmented in MS patients; 2) PD1- T(reg) cells were significantly increased in the peripheral blood of patients with stable disease (SMS) compared to those with acute (AMS) disease, and in patients responding to glatiramer acetate (COPA) compared to AMS- and COPA-unresponsive patients; and 3) PD1+ T(reg) cells were similar in CSF and peripheral blood of all groups analyzed. PD1- T(reg) cells were not increased in the peripheral blood of interferon-beta (IFNbeta) -responsive patients, but the suppressive ability of T(reg) cells was significantly higher in SMS and in COPA- or IFNbeta-responsive compared to AMS- and COPA-unresponsive individuals. The data herein suggest that PD1- T(reg) cells play a pivotal role in MS and offer a biological explanation for disease relapse and for the mechanism associated with response to COPA and IFNbeta.


Assuntos
Imunossupressores/uso terapêutico , Esclerose Múltipla Recidivante-Remitente/tratamento farmacológico , Esclerose Múltipla Recidivante-Remitente/imunologia , Linfócitos T Reguladores/imunologia , Adulto , Antígenos CD/biossíntese , Proteínas Reguladoras de Apoptose/biossíntese , Antígenos CD4/imunologia , Líquido Cefalorraquidiano/imunologia , Progressão da Doença , Feminino , Fatores de Transcrição Forkhead/imunologia , Acetato de Glatiramer , Humanos , Interferon gama/uso terapêutico , Subunidade alfa de Receptor de Interleucina-2/imunologia , Masculino , Pessoa de Meia-Idade , Proteína Básica da Mielina/metabolismo , Peptídeos/uso terapêutico , Receptor de Morte Celular Programada 1 , Linfócitos T Reguladores/efeitos dos fármacos
3.
J Pediatr ; 149(5): 611-6, 2006 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-17095329

RESUMO

OBJECTIVES: To test whether secretory immunoglobulin A (sIgA) to human immunodeficiency virus (HIV) antigens in breast milk of HIV-positive women is associated with protection against HIV transmission among breast-fed infants. STUDY DESIGN: Nested, case-control design in which HIV-specific sIgA was measured in breast milk collected from 90 HIV-positive women enrolled in a study in Lusaka, Zambia. Milk samples were selected to include 26 HIV-positive mothers with infected infants (transmitters) and 64 mothers with uninfected infants (nontransmitters). RESULTS: HIV-specific sIgA was detected more often in breast milk of transmitting mothers (76.9%) than in breast milk of nontransmitting mothers (46.9%, P = .009). There were no significant associations between HIV-specific sIgA in breast milk and other maternal factors, including HIV RNA quantities in breast milk, CD4 count, and plasma RNA quantities. CONCLUSIONS: HIV-specific sIgA in breast milk does not appear to be a protective factor against HIV transmission among breast-fed infants.


Assuntos
Infecções por HIV/imunologia , Infecções por HIV/prevenção & controle , HIV-1/imunologia , Imunoglobulina A Secretora/imunologia , Transmissão Vertical de Doenças Infecciosas/prevenção & controle , Leite Humano/imunologia , Adulto , Especificidade de Anticorpos , Biomarcadores/sangue , Aleitamento Materno , Contagem de Linfócito CD4 , Estudos de Casos e Controles , Feminino , Seguimentos , Infecções por HIV/epidemiologia , Infecções por HIV/transmissão , Humanos , Imunoglobulina A Secretora/administração & dosagem , Recém-Nascido de Baixo Peso , Recém-Nascido , Modelos Logísticos , Masculino , Análise Multivariada , RNA Viral/sangue , Fatores de Risco , Carga Viral , Zâmbia
4.
Vaccine ; 24(9): 1470-7, 2006 Feb 27.
Artigo em Inglês | MEDLINE | ID: mdl-16221513

RESUMO

HIV-1 Immunogen is a gp120-depleted whole killed virus vaccine candidate formulated with Incomplete Freund's Adjuvant (HIV-IFA). We evaluated in a mouse model the immunogenicity of HIV-IFA by itself and when combined with HYB2055, an immunomodulatory oligonucleotide consisting of a novel DNA structure and synthetic CpR immunostimulatory motif, as an adjuvant. C57/BL6 mice were immunized with HIV-IFA alone or combined with HYB2055. Mice treated with HYB2055 or with PBS were used as controls. Compared to HIV-IFA alone, immunization with HIV-IFA and HYB2055 combination elicited strong production of HIV- and p24-specific IFNgamma, RANTES, MIP 1alpha, and MIP 1beta, as well as high titers of HIV- and p24-specific antibodies. Inclusion of HYB2055 also reduced levels of IL-5 produced by HIV-IFA alone. HYB2055 enhances the immunogenicity of HIV-IFA and shifts responses towards a type 1 cytokine profile. The immune enhancing effects of HYB2055 adjuvant were dose-dependent. These findings warrant clinical evaluation of the HIV-1 immunogen/HYB2055 candidate as a therapeutic vaccine for HIV-1 infected patients.


Assuntos
Vacinas contra a AIDS/imunologia , Oligonucleotídeos/farmacologia , Vacinas contra a AIDS/administração & dosagem , Animais , Células Cultivadas , Quimiocina CCL3 , Quimiocina CCL4 , Quimiocina CCL5/biossíntese , Citocinas , Quimioterapia Combinada , Feminino , Anticorpos Anti-HIV/sangue , Proteína gp120 do Envelope de HIV , Interferon gama/biossíntese , Interleucina-5/biossíntese , Linfócitos/imunologia , Proteínas Inflamatórias de Macrófagos/biossíntese , Camundongos , Camundongos Endogâmicos C57BL , Oligonucleotídeos/administração & dosagem
5.
J Acquir Immune Defic Syndr ; 39(2): 138-42, 2005 Jun 01.
Artigo em Inglês | MEDLINE | ID: mdl-15905728

RESUMO

Alpha-defensins have been observed to have anti-HIV activity but have not been investigated in relation to mother-to-child HIV transmission. We measured the concentration of alpha-defensins in breast milk of HIV-positive mothers and tested whether the concentrations were associated with HIV transmission. A nested case-control study of 32 HIV-positive women who transmitted HIV to their infants and 52 randomly selected HIV-positive women who did not transmit HIV to their infants was conducted in Lusaka, Zambia. alpha-Defensins were detected in most (79%) of the milk samples tested. Concentrations of alpha-defensins increased as breast milk HIV RNA quantity increased, and breast milk HIV RNA quantity was, in turn, a strong and significant predictor of HIV transmission. After adjustment for milk HIV RNA quantity, however, alpha-defensin concentration was significantly associated with a decreased risk of intrapartum and postnatal HIV transmission (odds ratio = 0.3, 95% confidence interval: 0.09-0.93). Our data suggest that there may be a role for alpha-defensins in prevention of HIV transmission to breastfed infants.


Assuntos
Infecções por HIV/prevenção & controle , Transmissão Vertical de Doenças Infecciosas/prevenção & controle , Leite Humano/química , Leite Humano/virologia , alfa-Defensinas/análise , Adulto , Aleitamento Materno , Contagem de Linfócito CD4 , Estudos de Casos e Controles , Infecções por HIV/transmissão , Soropositividade para HIV , Humanos , Análise Multivariada , RNA Viral/análise , RNA Viral/genética , RNA Viral/isolamento & purificação , Zâmbia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...